Board member leaves IRLAB for another assignment

December 31, 2021 Regulatory

IRLAB (Nasdaq Stockholm: IRLAB A). Martin Nicklasson has announced his intention to leave the board in January 2022. The background to this decision is his new role as chairman of the board in another company.

Read More >

IRLAB obtains regulatory approval to conduct Phase IIb study with pirepemat – one step closer to improving balance and reducing fall injuries for people living with Parkinson’s disease

December 21, 2021 Regulatory

IRLAB (Nasdaq Stockholm: IRLAB A) IRLAB receives regulatory approval from the Swedish MPA for conducting a Phase IIb study with the investigational drug candidate pirepemat. Following approvals from regulatory authorities in additional participating countries and from ethics committees, patient recruitment will start in Q1, 2022. Recruitment is expected to continue for 18 months.

Read More >

IRLAB publishes interim report for July 1 – September 30, 2021

November 10, 2021 Regulatory

IRLAB today published its interim report for the third quarter 2021 (July 1 – September 30, 2021)

Read More >


IR contact

Viktor Siewertz, CFO
+46(0)72 710 70 70

Upcoming events